Frequency and type of KRAS mutations in routine diagnostic analysis of metastatic colorectal cancer
J Neumann, E Zeindl-Eberhart, T Kirchner… - Pathology-Research and …, 2009 - Elsevier
Mutation analysis of the KRAS oncogene is now established as a predictive biomarker in
colorectal cancer (CRC). Large prospective clinical trials have shown that only CRCs with
wild-type KRAS respond to anti-epidermal growth factor receptor (EGFR) treatment.
Therefore, mutation analysis is mandatory before treatment, and reliable benchmarks for the
frequency and types of KRAS mutations have to be established for routinely testing large
numbers of metastatic CRCs. A thousand and eighteen cases (879 primary tumors and 139 …
colorectal cancer (CRC). Large prospective clinical trials have shown that only CRCs with
wild-type KRAS respond to anti-epidermal growth factor receptor (EGFR) treatment.
Therefore, mutation analysis is mandatory before treatment, and reliable benchmarks for the
frequency and types of KRAS mutations have to be established for routinely testing large
numbers of metastatic CRCs. A thousand and eighteen cases (879 primary tumors and 139 …
